This site is intended for health professionals only
Anticoagulants are used for the treatment of DVT or PE, to prevent recurrence and to reduce the risk of secondary complications, such as post-thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTEPH).1-3
The phases of anticoagulation treatment may be categorised as ‘active’ and ‘long-term’.4 The first phase is considered to be active treatment of acute VTE and secondary prevention, whereas the second phase is considered to be secondary prevention only.4
More information on anticoagulants for the treatment of VTE and secondary prevention of VTE is provided later.
In Treatment of VTE: Treatment of VTE | Anticoagulation for the management of VTE | Initial management of a confirmed VTE | DOACs for the treatment of VTE and prevention of recurrent VTE |
CTEPH=Chronic Thromboembolic Pulmonary Hypertension DOAC=Direct-acting Oral Anticoagulant DVT=Deep Vein Thrombosis MHRA=Medicines and Healthcare products and Regulatory Agency PE=Pulmonary Embolism PTS=Post-Thrombotic Syndrome SmPC=Summary of Product Characteristics VTE=Venous Thromboembolism
Sign up for news alerts and don't miss out
Subscribe to Pulse's newsletters to ensure you receive the news as it happens.
Sharpen your skills and further your career with Pulse
Sign up for news alerts and don't miss out
Subscribe to Pulse's newsletters to ensure you receive the news as it happens.
Sharpen your skills and further your career with Pulse